L-Folinic acid

Phase 3Small molecule

IInstitut Cancerologie de l'Ouest

L-Folinic acid is one of 58 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Biliary Tract CancerActive, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Biliary Tract CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Lumakras

Amgen

Phase 3

2 2

Lynparza

AstraZeneca

Phase 3

2 3

Cyramza

Eli Lilly

Phase 3

2 4

Alinia

RRomark Laboratories L.C.

Phase 3

1 5

Cecon

MMcGuff Pharmaceuticals, Inc.

Phase 3

1 6

Cosela

PPharmacosmos A/S

Phase 3

1 7

Xeloda

Roche

Phase 3

3 8

Investigator's Choice Chemotherapy

Genmab

Phase 3

1 9

HX008

BBinhui Biopharmaceutical Co., Ltd.

Phase 3

1 10

Eylea

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Metastatic Colorectal Cancer

NCT06509126

Clinical

Trials by Indication[1]

Peritoneal Metastases1 trial

Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers

Terminated·IInstitut Cancerologie de l'Ouest·Phase 1/2·NCT03294252·34 enrolled

Biliary Tract Cancer1 trial

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

Completed·TThe Christie NHS Foundation Trust·Phase 3·NCT01926236·162 enrolled

Metastatic Colorectal Cancer1 trial

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

Recruiting·NNational Cancer Institute, Naples·Phase 3·NCT06509126·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for L-Folinic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-Folinic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-Folinic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut Cancerologie de l'Ouest company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInstitut Cancerologie de l'Ouest

L-Folinic acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Peritoneal Metastases1 trial

Biliary Tract Cancer1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News